Overview

Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus

Status:
Recruiting
Trial end date:
2021-10-30
Target enrollment:
Participant gender:
Summary
This is a phase Ib placebo-controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of SY-009 after Multiple Ascending Doses in patients with Type 2 Diabetes Mellitus (T2DM).
Phase:
Phase 1
Details
Lead Sponsor:
Suzhou Yabao Pharmaceutical R&D Co., Ltd.